Home / News / Pearce IP Blog
Significant biosimilar activities this week include: 27 Jul 22 | AU | Viatris (Mylan) seeks PBS listing for etanercept...
Significant biosimilar activities this week include: 25 Jul 22 | US | FDA accepts ABLA for natalizumab biosimilar...
Depression, anxiety and related disorders are serious conditions whose treatment is - in many cases - not adequately...
Introduction Medicinal cannabis is now widely available in Australia. However, the vast majority of medicinal...
In the first such judgment since the 1980s, Justice Moshinsky has granted an interlocutory injunction to prevent TMA...
31 March 22 | Fresenius Kabi announced that it has bought a majority stake (55%) in mAbxience, a company specialising...
In its 2022-23 Budget, the Coalition Government has stated that it will continue to fund litigation against originator...
In the Coalition Government’s Budget for the financial year 2022-23, it sets out the investments that it would make...
Introduction The decision of the High Court in H. Lundbeck A/S v Sandoz Pty Ltd [2022] HCA 4 (Lundbeck) last week...
We previously wrote that, from 24 March 2022, individuals, businesses and organisations with an Australian presence...
Originally published in World Intellectual Property Review 3 2021 After surviving the Great Patent Cliff of 2011–2016,...
The Full Federal Court has held a supplier of cosmetic products (Self Care) liable to Allergan for infringing its...
New .au domain names will be available in Australia from 24 March 2022. From this date, individuals, businesses and...
A recent decision of Justice Burley in the Federal Court of Australia confirms that the bar for sufficiency and...
Although Australia has taken steps in recent years to harmonise its patent laws with those around the globe,...
Recent decisions of the Australian Federal Court reinforce the need for exclusive patent licences to include all...